InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,554.25
(
0.20%
)
US TECH 100
18,971.20
(
-0.03%
)
Dow Jones
40,659.76
(
0.24%
)
Brent Oil
79.17
(
0.00%
)
Bitcoin
59,488.48
(
0.03%
)

Replies to post #23861 on OncoSec Medical Inc (ONCSQ)

Replies to #23861 on OncoSec Medical Inc (ONCSQ)
icon url

Ninja Master

10/16/14 10:04 AM

#23862 RE: cameron12x #23861

Nice. I like the fact that even the author describes the IIb trials as a given and that they are "setting up" for it.
icon url

twiz0019

10/16/14 10:17 AM

#23864 RE: cameron12x #23861

Great post cameron....awesome find!
icon url

LifterPuller

10/16/14 10:21 AM

#23865 RE: cameron12x #23861

From Zacks:

And we estimate approval of ImmunoPulse for the treatment of melanoma may be obtained as early as in late 2017 if the pivotal trial data prove to be positive.



Does this seem late to anyone else? I'm a biotech newb, but Pierce has stated a couple of times he doesn't think a P3 will be needed. Wouldn't that change the timeline to late 2015 or 2016?